Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy

Objectives To estimate mortality rates and prognostic factors in HIV-positive patients who started combination antiretroviral therapy between 1996–1999 and survived for more than ten years. Methods We used data from 18 European and North American HIV cohort studies contributing to the Antiretroviral Therapy Cohort Collaboration. We followed up patients from ten years after start of combination antiretroviral therapy. We estimated overall and cause-specific mortality rate ratios for age, sex, transmission through injection drug use, AIDS, CD4 count and HIV-1 RNA. Results During 50,593 person years 656/13,011 (5%) patients died. Older age, male sex, injecting drug use transmission, AIDS, and low CD4 count and detectable viral replication ten years after starting combination antiretroviral therapy were associated with higher subsequent mortality. CD4 count at ART start did not predict mortality in models adjusted for patient characteristics ten years after start of antiretroviral therapy. The most frequent causes of death (among 340 classified) were non-AIDS cancer, AIDS, cardiovascular, and liver-related disease. Older age was strongly associated with cardiovascular mortality, injecting drug use transmission with non-AIDS infection and liver-related mortality, and low CD4 and detectable viral replication ten years after starting antiretroviral therapy with AIDS mortality. Five-year mortality risk was <5% in 60% of all patients, and in 30% of those aged over 60 years. Conclusions Viral replication, lower CD4 count, prior AIDS, and transmission via injecting drug use continue to predict higher all-cause and AIDS-related mortality in patients treated with combination antiretroviral therapy for over a decade. Deaths from AIDS and non-AIDS infection are less frequent than deaths from other non-AIDS causes.

[1]  C. Larsen,et al.  Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study , 2016, Journal of acquired immune deficiency syndromes.

[2]  J. Sterne,et al.  Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration , 2015, Journal of acquired immune deficiency syndromes.

[3]  J. Blanco,et al.  HIV integrase inhibitors: a new era in the treatment of HIV , 2015, Expert opinion on pharmacotherapy.

[4]  M. Battegay,et al.  Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study , 2015, HIV medicine.

[5]  B. Yip,et al.  AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. , 2015, The lancet. HIV.

[6]  A. Mocroft,et al.  Regional differences in self-reported HIV care and management in the EuroSIDA study , 2014, Journal of the International AIDS Society.

[7]  O. Kirk,et al.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.

[8]  S. WellsJessica,et al.  An integrative review of guidelines for anal cancer screening in HIV-infected persons. , 2014 .

[9]  A. Mocroft,et al.  A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe , 2014, Infection.

[10]  J. Sterne,et al.  Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). , 2014, International journal of epidemiology.

[11]  S. Jensen-Fangel,et al.  Adherence to the cervical cancer screening program in women living with HIV in Denmark: comparison with the general population , 2014, BMC Infectious Diseases.

[12]  Kholoud Porter,et al.  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy , 2014, AIDS.

[13]  J. Sterne,et al.  Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  F. Maggiolo,et al.  Single-Tablet Regimens in HIV Therapy , 2014, Infectious Diseases and Therapy.

[15]  J. Rockstroh,et al.  Causes of death in HIV-infected patients from the Cologne–Bonn cohort , 2014, Infection.

[16]  Edward J. Mills,et al.  Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis , 2013, AIDS.

[17]  Timothy R Sterling,et al.  An internationally generalizable risk index for mortality after one year of antiretroviral therapy , 2013, AIDS.

[18]  Anne M Johnson,et al.  Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic , 2013, PloS one.

[19]  J. Sterne,et al.  Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. , 2012, International journal of epidemiology.

[20]  Kathy Petoumenos,et al.  Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy , 2012, PloS one.

[21]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[22]  A. Mocroft,et al.  All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. , 2012, International journal of epidemiology.

[23]  B. Gazzard,et al.  CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE , 2012, PLoS medicine.

[24]  A. Mocroft,et al.  Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy , 2012, AIDS.

[25]  H. Sørensen,et al.  Impact of Non-HIV and HIV Risk Factors on Survival in HIV-Infected Patients on HAART: A Population-Based Nationwide Cohort Study , 2011, PloS one.

[26]  J. Sterne,et al.  The Coding Causes of Death in HIV (CoDe) Project: Initial Results and Evaluation of Methodology , 2011, Epidemiology.

[27]  A. Justice,et al.  Cancer Screening in Patients Infected with HIV , 2011, Current HIV/AIDS reports.

[28]  A. Mocroft,et al.  A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study , 2011, HIV clinical trials.

[29]  S. Leone,et al.  Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort , 2011, Infection.

[30]  O. Kirk,et al.  Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study , 2010, AIDS.

[31]  Ross J. Harris,et al.  Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  A. Mocroft,et al.  Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV‐1‐infected patients treated with abacavir , 2010, HIV medicine.

[33]  Ross J. Harris,et al.  Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements , 2009, AIDS.

[34]  H. Furrer,et al.  Uptake of and virological response to antiretroviral therapy among HIV‐infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study , 2009, HIV medicine.

[35]  O. Kirk,et al.  HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies , 2008, AIDS.

[36]  P. Morlat,et al.  Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic) , 2008, Journal of acquired immune deficiency syndromes.

[37]  S. Swain,et al.  Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia. , 2007, The American journal of pathology.

[38]  C. Katlama,et al.  HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population , 2007, Journal of acquired immune deficiency syndromes.

[39]  J. Sterne,et al.  Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies , 2007, AIDS.

[40]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[41]  J. Sterne,et al.  Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. , 2005, Journal of clinical epidemiology.

[42]  P. Royston,et al.  Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.

[43]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[44]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[45]  Kyoung Soo Lee,et al.  Thoracic sequelae and complications of tuberculosis. , 2001, Radiographics : a review publication of the Radiological Society of North America, Inc.

[46]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[47]  B. Yip,et al.  Trends in AIDS incidence and AIDS-related mortality in British Columbia between 1981 and 2013 , 2015 .

[48]  T. Thomas,et al.  An integrative review of guidelines for anal cancer screening in HIV-infected persons. , 2014, AIDS patient care and STDs.

[49]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .